At a median follow-up of 40.9 months, acalabrutinib was non-inferior to ibrutinib on the primary endpoint of IRC-assessed PFS (HR: 1.00 [95% CI: 0.79, 1.27])¹

Acalabrutinib demonstrated lower frequencies of common AEs, grade ≥3 AEs, SAEs, and lower treatment discontinuations due to AEs overall²

• The incidence of grade ≥3 events were lower with acalabrutinib in high-risk patients with del(17p)
• Time to treatment discontinuation overall was longer with acalabrutinib

Cardiovascular events were less common with acalabrutinib vs ibrutinib² 

• Afib/flutter events (any grade) were significantly less frequent with acalabrutinib vs ibrutinib (9.4% vs 16%; P=0.02)
• Hypertension (any grade) was also less frequent with acalabrutinib vs ibrutinib (9.4% vs 23.2%)

ECIs overall, as well as hypertension and atrial fibrillation/flutter were also less prevalent each year with acalabrutinib² 

Among other secondary endpoints:¹

• Incidence of grade ≥3 infections and Richter transformation were comparable between arms
• Median OS was not reached in either arm

These results demonstrate that acalabrutinib is better tolerated and has similar efficacy to ibrutinib in patients with previously treated CLL²